A randomized, open-label, parallel-group, 18-month Phase 3 study to evaluate the effect of venglustat compared with usual standard of care on left ventricular mass index in participants with Fabry disease and left ventricular hypertrophy

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 16 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Venglustat (Primary) ; Agalsidase alfa; Agalsidase beta; Migalastat
Indications Fabry's disease; Left ventricular hypertrophy
Focus Therapeutic Use
Acronyms CARAT
Sponsors Sanofi Genzyme; Sanofi-Aventis Recherche & Developpement

Most Recent Events

17 Dec 2024 Planned End Date changed from 15 Jul 2027 to 6 Dec 2027.
17 Dec 2024 Planned primary completion date changed from 29 Dec 2025 to 15 May 2026.
17 Dec 2024 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight